Trial Profile
A randomised phase 2 study of paclitaxel with or without GSK1120212 or pazopanib in advanced wt BRAF melanoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 04 Jul 2023
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary) ; Trametinib (Primary) ; Paclitaxel
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms PACMEL
- 14 Nov 2018 Results published in the Annals of Oncology
- 05 Apr 2017 Results of phase II part of this study (n=111) presented at the 108th Annual Meeting of the American Association for Cancer Research
- 11 Apr 2016 Status changed from recruiting to completed.